peptide nasal spray bpc-157 / Thymosin Beta-4 BPC-157 + TB-500 Nasal Spray

[2] [11] As of 2026, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental compound available only within authorised clinical trial settings

Giudice, J., & Taylor, J

General Safety Adults tolerate it well for both subcutaneous and intramuscular injection

Keep a small piece of tape or a note on the vial box and write down each time you remove it from the refrigerator, along with the approximate duration

This is not a BPC-157-specific problem

May help support the bodys natural healing processes following minor injuries